


AUTHOR QUERY FORM

	Journal: AGG	Please e-mail or fax your responses and any corrections to:
ELSEVIER	Article Number: 2414	E-mail: corrections.esil@elsevier.thomsondigital.com
		Fax: +353 6170 9272

Dear Author,

Please check your proof carefully and mark all corrections at the appropriate place in the proof (e.g., by using on-screen annotation in the PDF file) or compile them in a separate list.

For correction or revision of any artwork, please consult <http://www.elsevier.com/artworkinstructions>.

No queries have arisen during the processing of your article.


Thank you for your assistance.



Contents lists available at ScienceDirect

Archives of Gerontology and Geriatrics

journal homepage: www.elsevier.com/locate/archger



1
2
3
4

Allergic rhinitis (AR) in geriatric patients

Hayriye Karabulut*, Selcan Baysal, Baran Acar, Mehmet Ali Babademez, Riza Murat Karasen

Department of Otolaryngology, Ankara Keçioren Research and Training Hospital, Vadi konutlari B Blok D, 4 Subayevleri Keçioren, 06130 Ankara, Turkey

ARTICLE INFO

Article history:

Received 11 August 2010
Received in revised form 3 December 2010
Accepted 4 December 2010

Keywords:

Allergic rhinitis
Skin prick test
Geriatric allergy

ABSTRACT

Allergic rhinitis (AR) can be defined as an inflammatory disease of the nose and the paranasal sinuses, characterized by a specific IgE-mediated hypersensitivity reaction. The aim of this study was to evaluate the correlation between the symptoms of AR and the prick test results in geriatric patients presenting with symptoms of AR by comparing these with those of a young control group. Thirty-two geriatric patients (Group 1) were analyzed retrospectively, and 37 patients (Group 2) were selected as the control group. Diagnosis of AR was made based upon the physical examination findings, nasal endoscopic examination findings and the skin prick test results. While the skin prick test positivity was 50% in Group 1, this rate was found as 75.7% in Group 2. The difference was found to be statistically significant ($p = 0.044$). A statistically significant difference was found between the two groups in terms of susceptibility to mugwort pollen and fish ($p = 0.048$, $p = 0.033$). In conclusion, in geriatric patients presenting with AR symptoms, systemic treatment should not be initiated before performing skin prick test, due to the adverse effects of the drugs.

© 2010 Published by Elsevier Ireland Ltd.

5
6

1. Introduction

The geriatric population is predicted to increase in the future according to the WHO. The rate of individuals above 65 years of age has been reported to be approximately 20% in Europe (Bom and Pinto, 2009). The long life expectation is considered to be related to decreased rate of infectious diseases owing to better hygiene, common antibiotic use and vaccination. Chronic diseases have an important place among factors that lead to deterioration in the quality of life and death in the geriatric population owing to the increase in life span in developed countries. Wide closed areas, use of artificial products, breeding domestic animals, living in damp houses and fungi in the environment generating along with modern life are among the factors triggering allergy (Merrett et al., 1980; Wuthrich et al., 1995). Vital functions and the lung capacity are decrease in individuals of 65 years and older (Harik-Khan et al., 1998). Allergic rhinitis (AR) can be defined as an inflammatory disease of the nose and the paranasal sinuses, characterized by a specific IgE-mediated hypersensitivity reaction, clinically arising following the exposure of the nasal mucosa to allergens. AR is characterized by sneezing, nasal obstruction, nasal itching, post-nasal drip and smell disorders. Ocular symptoms like eye itching, congestion, lividity, pulmonary symptoms like cough, dyspnea, wheezing, and dermatological symptoms such as eruption, itching,

rash, and urticaria can accompany nasal symptoms in patients with AR.

Allergic diseases are known to change with age, gender, race and genetic factors. Skin test responses have been found to be of a low degree in infants, young children and those above 50 years of age (Edis et al., 2007). The skin prick test is a widely used diagnostic skin test to indicate the IgE-related reaction in determination of allergens that lead to symptoms in patients with AR. These tests are cheap, easily applicable and yield a rapid result. In this study, we aimed to evaluate the correlation between the symptoms of AR and the prick test results in geriatric patients presenting with symptoms of AR by comparing these with those of a young control group.

2. Subjects and methods

2.1. Patient characteristics and follow-up

Patients with the prediagnosis of AR who had been followed-up with the allergy test in the Otorhinolaryngology Clinic between January 2008 and April 2010 were included in the study. Of the 1700 patients who underwent the allergy test with the prediagnosis of AR, files of 32 geriatric patients were analyzed retrospectively. A total of 372 patients aged between 40 and 45 years were sorted according to the dates of presentation to the clinic and 37 patients were selected by number of 10 and its times as the control group. Age, gender, presence of nasal, ocular, pulmonary and dermatological symptoms were recorded.

* Corresponding author. Tel.: +90 0312 356 9000; fax: +90 312 356 9002.
E-mail addresses: hayriyekarabulut@gmail.com, drhayriye@hotmail.com (H. Karabulut).

55 Diagnosis of AR was made based upon the physical examination
56 findings, nasal endoscopic examination findings and the skin prick
57 test results. Sneezing, runny nose, nasal obstruction and nasal
58 itching, presence of serous secretion in the nasal cavity, pale nasal
59 mucosa, edemateous, and pale or purplish conchae were inter-
60 preted in favor of AR. Patients were analyzed in terms of skin
61 findings and presence of erythema, itching, urticaria and eruption
62 and these were recorded. Cough, dyspnea and wheezing were
63 investigated as pulmonary symptoms. Itching, redness and edema
64 were questioned as ocular symptoms.

65 Alyostal ST-IR (Stallegenes S.A. France) standard allergen
66 extracts were used for the skin prick test. For the test,
67 antihistamines had to be withdrawn 10 days previously, H2
68 receptor blockers had to be withdrawn 24 h previously, and
69 antidepressant drugs withdrawn 20 days previously. Allergen
70 extracts that were taken in standard doses in quick test applicators
71 with 8 distinct edges were applied onto the skin after having
72 cleaned the ventral part of the forearm with alcohol. The results
73 were evaluated 15 min later. Histamine-HCl was used as positive
74 control and isotonic NaCl was used as negative control. The validity
75 criterion for the test was accepted as >3 mm for positive control
76 and <3 mm for negative control. Skin reaction against the allergen
77 with an enduration of >3 mm in diameter was accepted as a
78 positive reaction (Polosa et al., 2005).

79 The most common 30 allergen extracts and positive and
80 negative controls were applied using a total of 4 applicators onto
81 the skin of forearm for the skin prick test. Two house dust mites, 3
82 fungal spores, 1 insect, 3 animal epithelia, 15 pollens and 6 food
83 allergens were used.

84 The skin prick test was not applied on patients who had been
85 treated with the diagnosis of asthma, or on those who had
86 suspicion of asthma and who were on beta-blocker agents.

87 **2.2. Statistical analysis**

88 Statistical analysis was performed using the SPSS 15.0 program.
89 Consistency of the data with a normal distribution was assessed
90 using the Kolmogorov-Smirnov test. Parametric measurements
91 were elaborated by using the intergroup independent sample *t*-
92 test and the non-parametric measurements were made using the
93 Wilcoxon and the Mann-Whitney *U*-test. A *p* < 0.05 was consid-
94 ered statistically significant.

95 **3. Results**

96 Of the 69 patients, 32 were above 65 years of age (Group 1), and
97 37 were aged between 40 and 45 years (Group 2). Of the patients in
98 Group 1, 21 were females (65.6%), 11 were males (34.4%); of the
99 patients in Group 2, 27 were females (73%) and 10 were (27%)
100 males, and a significant difference was not found between the two
101 genders. Nasal symptoms were scored out of 7 points, ocular
102 symptoms were scored out of 3 points and pulmonary symptoms
103 were scored out of 3 points and comparisons were made. The total
104 symptom scores have been presented in Table 1. Nasal symptoms
105 are displayed in Fig. 1, and dermatological, ocular and pulmonary
106 symptoms are displayed in Table 2. There was no significant
107

Table 1
Mean total symptom scores in the 2 groups, mean ± S.D.

	Group 1	Group 2
Nasal symptoms	3.4 ± 1.6	4.1 ± 1.3
Eye symptoms	1.7 ± 0.8	1.6 ± 1.0
Pulmonary symptoms	1.3 ± 1.1	1.4 ± 1.0
Dermatologic symptoms	1.2 ± 1.5	1.4 ± 1.3

Notes: for all group-differences (*p* > 0.05).




Fig. 1. Frequency of nasal symptoms (*p* > 0.05).

Table 2
Frequency (%) of ocular, pulmonar, and dermatologic symptoms.

	Group 1	Group 2
Itching eye	87.1	73.0
Red eyes	58.1	54.1
Eye edema	25.8	37.8
Coughing	54.8	54.1
Dyspnea	48.4	54.1
Wheezing	32.3	35.1
Skin eruption	25.8	40.5
Skin itch	40.9	48.6
Skin erythema	38.7	40.5
Urticaria	22.6	16.2

107 difference between the groups in terms of symptoms on
108 presentation and nasal examination findings.

109 While the skin prick test positivity was 50% in Group 1, this rate
110 was found as 75.7% in Group 2. The difference was found to be
111 statistically significant (*p* = 0.044).

112 All the cases in both groups had at least one of the nasal
113 symptoms. The rate of having one of the ocular symptoms was
114 90.3% in Group 1 and 83.3% in Group 2. The likelihood of having any
115 of the pulmonary symptoms was 71% in Group 1 and 78.4% in
116 Group 2. The likelihood of having any of the dermatological
117 symptoms was 51.6% in Group 1 and 64.9% in Group 2. The
118 frequency of symptoms was similar in both groups (*p* > 0.05).

119 The number of the allergens to which patients with positive
120 skin prick test were susceptible was 6.1 ± 5.8 (1-19) in Group 1 and
121 7.4 ± 6.1 (1-23) in Group 2, and no significant difference was found
122 (*p* = 0.32). A statistically significant difference was found between the
123 two groups in terms of susceptibility to mugwort pollen and fish.
124 Susceptibility to mugwort pollen was found as 12.5% in the elderly
125 group and 35.1% in the young group (*p* = 0.048). Susceptibility to fish
126 was found to be 3.2% in the elderly group and 2.6% in the young group
127 (*p* = 0.033).

128 **4. Discussion**

129 AR is an inflammatory disease of the mucous membranes
130 developing related to type 1 hypersensitivity reaction. Type 1
131 hypersensitivity reaction is also referred to as early hypersensitiv-
132 ity, and IgE located on the surfaces of basophils and mast cells plays
133 a role in this reaction (Prussin and Metcalfe, 2006). The allergen is
134 usually the inhalant particles in AR and this phenomenon begins
135 with T-cell, B-cell and plasma cell cascade. Specific antigen binds
136 with two specific IgE antibodies on the surfaces of mast cells
137 located in the mucosa of the respiratory and gastrointestinal

system, subconjunctiva and subcutaneous layer of the skin. This IgE-mediated reaction then leads to mast cell degranulation and triggers the development of an inflammation by release of histamine, leukotriene, cytokine, prostoglandin and platelet activating factor. This is called the early phase or humoral reaction and occurs in 10–15 min following allergen exposure (Prussin and Metcalfe, 2006).

Release of histamine is responsible for sneezing, runny nose, itching, increase in vascular permeability, vasodilation and hypersecretion of the glands. Release of cytokines and leukotrienes causes the migration of inflammatory cells, mainly eosinophils, toward the affected area. This inflammatory response is the delayed phase or the cellular reaction, and begins 4–6 h after the first sensitization and it can prolong the allergic cascade up to 48 h and increase its severity. This response is mainly responsible for nasal congestion and post-nasal drip in AR (Kay, 2001). In our study, the rates of nasal congestion were found as 78.4% in the young and 61.3% in the elderly; post-nasal drip was found as 81.1% in the young and 61.3% in the elderly. When these results are taken into consideration, it can be concluded that allergic nasal symptoms are more common among the young compared to the elderly, despite the fact that this is statistically insignificant.

Although AR is common in the young population, its prevalence is gradually increasing among the elderly. The reason for this is desensitization developing in the past years and decrease in outdoor exposure. Studies have shown that higher exposure of the elderly to indoor allergens increases the amount of IgE against these allergens and mite allergen positivity in the skin prick test (Rogers et al., 2002; King and Lockey, 2003). In our study, the number of allergen sensitivity was found to be lower in the elderly compared to the young, which was consistent with the literature.

Concurrence of asthma and AR, which is a risk factor for development of asthma, is common and AR is present in 75% of asthmatic patients. Prevalence of asthma has been reported to vary between 10% and 40% in AR patients (Linneberg et al., 2002). Mortality rates are higher among asthmatic patients of 65 years and older compared to young asthmatic patients (Moorman et al., 2007).

Treatment of AR comprises environmental control, pharmacotherapy and immunotherapy. Intranasal and systemic antihistamines, intranasal and systemic corticosteroids, decongestants, intranasal anticholinergics, intranasal cromolone and leukotriene antagonists are used for pharmacotherapy (Howarth, 2003). In allergic disease, the main effects of histamine are upon histamine-1 (H-1) receptor; in hypotension, tachycardia, flushing and headache. Its effect is mediated by H-1 and H-2 receptors, and in skin itching and nasal congestion, its effect is mediated by H-3 and H-4 receptors (Tilgigada et al., 2009).

Antihistamines prevent reactions induced by histamine, such as increased vascular permeability, smooth muscle contraction, increased mucus production and itching, by blocking the H1 receptor areas. Antihistamines are effective in the early phase reaction and decrease symptoms like sneezing, runny nose, and itchy nose (Kay, 2001). They have very few effects on nasal congestion developing as a result of delayed phase reaction.

First generation antihistamines should be used carefully in old patients due to their adverse effects including sedation, memory disturbances, psychomotor dysfunction and anticholinergic adverse effects, whereas second generation antihistamines have less effects on the central nervous system as they permeate the blood-brain barrier to a lower extent (Bousquet et al., 2003).

Of the second generation antihistamines, terfenadine and astemizole have cardiac adverse effects (Estelle and Simons, 1999). This is a factor restricting their use in the elderly. Intranasal antihistamines are effective on itching, rhinorrhea and sneezing symptoms. Azelastine used twice a day decreases seasonal AR

symptoms not responding to oral antihistamines. It has adverse effects like mild sedation and metallic taste (Berger and White, 2003).

Medical history and diagnostic tests are used in the diagnosis of AR. Presence of 2 or more of the symptoms of watery rhinorrhea, sneezing, nasal obstruction and itchy nose lasting for more than 1 h in most days of the week should urge one to suspect AR. Skin test and serum specific IgE level are the diagnostic tests. Demonstration of susceptibility to specific antigens with the skin test is essential in the diagnosis of AR (Murphree and Kniker, 1979). The skin prick test is the most sensitive test that can be applied easily in the diagnosis of AR (Brown et al., 1985; Scolozz et al., 1989; Akbas and Saatci, 2003). Prevalence of AR decreases with age (Jones, 2004). Richards et al. (1992) reported that the incidence of AR decreased above the age of 45. In our study, while the positivity of the skin prick test were found to be 50% in the elderly, it was found as 70% in the young, which consistent with the literature.

AR can be defined as an inflammatory disease of the nose characterized with specific IgE-mediated hypersensitivity reaction, clinically arising following exposure of the nasal mucosa to allergens. This condition can also be defined as allergic rhinosinusitis as it also affects the paranasal sinuses (Guerra et al., 2002). Allergy is a predisposing factor for chronic rhinosinusitis (Sanders, 1971). Diagnostic tests must be performed for AR, especially in the treatment of the elderly, owing to its high morbidity.

Vasomotor rhinitis is a condition triggered by alterations in various smells, heat and pressure, and characterized with nasal obstruction, rhinorrhea and nasal congestion (Druce, 1998). Vasomotor rhinitis is non-AR, the prevalence of which increases with age and is related to autonomic dysregulation of nasal functions (Bickmore, 1981). Performing skin tests before initiating the treatment of AR considering the probability of vasomotor rhinitis is a safe way to avoid the adverse effects of the drugs, as it is not IgE-mediated (Li, 2002). In our study, although the symptoms were more frequent among the young compared to the elderly who had presented with symptoms of AR, the difference was not found to be statistically significant. The skin prick test is an important diagnostic tool for AR, and its importance is gradually increasing, especially in the geriatric population when adverse effects of the systemic drugs used for treatment are taken into consideration.

According to the results of our study, in geriatric patients presenting with AR symptoms, systemic treatment should not be initiated before performing skin prick test, due to the adverse effects of the drugs.

Conflict of interest statement

None.

References

- Akbas, Y., Saatci, M.R., 2003. Monitoring the efficacy of immunotherapy by symptom scores and the skin prick test in patients with allergic rhinitis. *Kulak Burun Bogaz Ihtis Derg.* 10, 221–225 (in Turkish).
- Berger, W.E., White, M.V., 2003. Efficacy of azelastine nasal spray in patients with an unsatisfactory response to loratadine. *Ann. Allergy Asthma Immunol.* 91, 205–211.
- Bickmore, J.T., 1981. Vasomotor rhinitis: an update. *Laryngoscope* 91, 1600–1605.
- Bom, A.T., Pinto, A.M., 2009. Allergic respiratory diseases in the elderly. *Respir. Med.* 103, 1614–1622.
- Bousquet, J., Van Cauwenberge, P., Bachert, C., Canonica, G.W., Demoly, P., Durham, S.R., Fokkens, W., Lockey, R., Meltzer, E.O., Mullol, J., Naclerio, R.M., Price, D., Simons, F.E., Vignola, A.M., Warner, J.O., 2003. European Academy of Allergy and Clinical Immunology (EAACI). Allergic Rhinitis and its Impact on Asthma (ARIA). Requirements for medications commonly used in the treatment of allergic rhinitis. *Allergy* 58, 192–197.
- Brown, C.R., Higgins, K.W., Frazer, K., Schoelz, L.K., Dyminski, J.W., Marinkovich, V.A., 1985. Simultaneous determination of total IgE and allergen specific IgE in serum by the MAST chemiluminescent assay system. *Clin. Chem.* 31, 1500–1505.

- 269 Druce, H.M., 1998. Allergic and nonallergic rhinitis. In: Middleton, Jr., E., Ellis, E.F.,
270 Yunginger, J.W., Reed, C.E., Adkinson, N.F., Busse, W.W. (Eds.), *Allergy: Principles*
271 *and Practice*. 5th ed. St. Louis, Mosby, pp. 1005-1016.
- 272 Edis, E.C., Tabakaodlu, E., Cadlar, T., Hatipodlu, O.N., Altýay, G., 2007. Skin prick test
273 results in patients from thrace region presenting with pulmonary symptoms.
274 *Med. J. Trakya Univ.* 24, 12-16.
- 275 Estelle, F., Simons, R., 1999. H1-receptor antagonists: safety issues. *Ann. Allergy*
276 *Asthma Immunol.* 83, 481-488.
- 277 Guerra, S., Sherrill, D.L., Martinez, F.D., Barbee, R.A., 2002. Rhinitis as an independent
278 risk factor for adult-onset asthma. *J. Allergy Clin. Immunol.* 109, 419-425.
- 279 Harik-Khan, R.I., Wise, R.A., Fozard, J.L., 1998. Determinants of maximal inspiratory
280 pressure. The Baltimore longitudinal study of aging. *Am. J. Respir. Crit. Care*
281 *Med.* 158, 1459-1464.
- 282 Howarth, P.H., 2003. Allergic and non-allergic rhinitis. In: Middleton, E.Jr., Ellis,
283 E.F., Yunginger, J.W., Reed, C.E., Adkinson, N.F., Busse, W.W. (Eds.), *Allergy*.
284 *Principles and Practice*, 6th ed., vol. II. St. Louis, Mosby, pp. 1253-1289.
- 285 Jones, N., 2004. Allergic rhinitis: aetiology, predisposing and risk factors. *Rhinology*
286 42, 49-56.
- 287 Kay, A.B., 2001. Allergy and allergic diseases. Second of two parts. *N. Engl. J. Med.*
288 344, 109-113.
- 289 King, M.J., Lockey, R.F., 2003. Allergen prick-puncture skin testing in the elderly.
290 *Drug Aging* 20, 1011-1017.
- 291 Li, J.T., 2002. Allergy testing. *Am. Fam. Physician* 66, 621-624.
- 292 Linneberg, A., Henrik Nielsen, N., Frolund, L., Madsen, F., Dirksen, A., Jorgensen, T.,
293 2002. The link between allergic rhinitis and allergic asthma: a prospective
294 population-based study. *The Copenhagen Allergy Study. Allergy* 57, 1048-1052.
- 295 Merrett, T.G., Pantin, C.F., Dimond, A.H., Merrett, J., 1980. Screening for IgE-medi-
296 ated allergy. *Allergy* 35, 491-501.
- Moorman, J.E., Rudd, R.A., Johnson, C.A., King, M., Minor, P., Bailey, C., Scalia, M.R.,
Akinbami, L.J., 2007. Centers for Disease Control and Prevention (CDC). National
surveillance for asthma: United States, 1980-2004. *MMWR Surveill. Summ.* 56,
1-54.
- Murphree, J.T., Kniker, W.T., 1979. Correlation of immediate skin test responses to
antigens introduced by multi-test and intracutaneous routes. *Ann. Allergy* 43,
279-285.
- Polosa, R., Al-Delaimy, W.K., Russo, C., Piccillo, G., Sarvf, M., 2005. Greater risk of
incident asthma cases in adults with allergic rhinitis and effect of allergen
immunotherapy: a retrospective cohort study. *Respir. Res.* 28, 153.
- Prussin, C., Metcalfe, D.D., 2006. 5. IgE, mast cells, basophils, and eosinophils. *J.*
Allergy Clin. Immunol. 117, S450-S456.
- Richards, S., Thornhill, D., Roberts, H., Harries, U., 1992. How many people think
they have hay fever, and what they do about it. *Br. J. Gen. Pract.* 42, 284-
286.
- Rogers, L., Cassino, C., Berger, K.I., Goldring, R.M., Norman, R.G., Klugh, T., Reibman,
J., 2002. Asthma in the elderly: cockroach sensitization and severity of airway
obstruction in elderly nonsmokers. *Chest* 122, 1580-1586.
- Sanders, S.H., 1971. Allergic rhinitis and sinusitis. *Otolaryngol. Clin. North. Am.* 4,
565-578.
- Scolozz, R., Boccafogli, A., Vincentini, L., Baraldi, A., Bagni, B., 1989. Correlation of
chemiluminescent (CLA) with RAST and skin prick test for diagnosis of inhalant
allergic diseases. *Ann. Allergy* 62, 193a-193b.
- Tiligada, E., Zampeli, E., Sander, K., Stark, H., 2009. Histamine H3 and H4 receptors as
novel drug targets. *Expert Opin. Invest. Drug* 18, 1519-1531.
- Wuthrich, B., Schindler, C., Leuenberger, P., Ackermann-Liebrich, U., 1995. Preva-
lence of atopy and pollinosis in the adult-population of Switzerland and
(Sapaldia study). *Int. Arch. Allergy Immunol.* 106, 149-156.

297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325